Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Vanlev Launch Resources Will Shift To Pravachol; NDA Withdrawn

Executive Summary

Bristol plans to reallocate some of the money reserved for the launch of the antihypertensive Vanlev to help revive the cholesterol-lowering agent Pravachol.

You may also be interested in...



Bristol Vanlev Second-Line Hypertension Use To Be Reviewed By FDA Cmte.

Bristol-Myers Squibb will ask an FDA advisory committee to recommend Vanlev for a second line hypertension indication, Exec VP Donald Hayden told the Goldman Sachs healthcare conference June 13 in Laguna Niguel, Calif

Bristol Vanlev Second-Line Hypertension Use To Be Reviewed By FDA Cmte.

Bristol-Myers Squibb will ask an FDA advisory committee to recommend Vanlev for a second line hypertension indication, Exec VP Donald Hayden told the Goldman Sachs healthcare conference June 13 in Laguna Niguel, Calif

Bristol Vanlev OCTAVE Data: Angioedema Risk Suggests Second-Line Use

Bristol-Myers Squibb's Vanlev OCTAVE data suggest that the review of the antihypertensive candidate will focus on a potential second-line indication to the ACE inhibitor enalapril

Related Content

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel